drugset
drugset / Trial / NCT00093743

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

NCT00093743 ↗

Phase 1 Completed 2 enrolled Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment

Summary

Based on success in other diseases, the Fred Hutchinson Cancer Research Center (FHCRC) has developed a transplant procedure for Fanconi anemia (FA), which does not completely destroy the patient's remaining bone marrow. It should also be less harmful (toxic). Researchers wish to test whether this approach can overcome the graft failure often seen when bone marrow or peripheral blood stem cells from an unrelated donor are used. Researchers also will look at whether the procedure is less toxic than a conventional bone marrow transplant (BMT).

Timeline

Start
2000-01
Primary completion
2007-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Background Cyclosporine Peptide — Intravenous
Background Fludarabine Small molecule — Intravenous
Background Mycophenolate Mofetil Small molecule — Oral

Indications

Fanconi anemia acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, del(5q31-q32) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) childhood acute myeloid leukemia childhood myelodysplastic syndrome